Patents by Inventor Jean-Claude Tardif

Jean-Claude Tardif has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Methods of treating acute respiratory distress syndrome using colchicine
    Patent number: 11844771
    Abstract: Disclosed are methods of treating Acute Respiratory Distress Syndrome using colchicine, e.g., by administering colchicine to a subject in need thereof.
    Type: Grant
    Filed: April 6, 2022
    Date of Patent: December 19, 2023
    Assignee: INSTITUT DE CARDIOLOGIE DE MONTREAL
    Inventors: Jean-Claude Tardif, Jocelyn Dupuis
  • Co-culture system and method for in vitro assessment of reverse cholesterol transport
    Patent number: 11840707
    Abstract: The present invention provides a co-culture system and method for assessing cellular cholesterol (Choi) efflux and uptake in vitro. The co-culture system mimics in vivo Choi efflux and uptake in the context of mammalian physiology. The methods and systems provided can be used in some embodiments to evaluate the effect of a pharmacological agent on cellular Choi efflux and uptake or for diagnostic purposes.
    Type: Grant
    Filed: May 30, 2017
    Date of Patent: December 12, 2023
    Assignee: INSTITUT DE CARDIOLOGIE DE MONTREAL
    Inventors: David Rhainds, Éric Rhéaume, David Busseuil, Jean-Claude Tardif
  • EARLY ADMINISTRATION OF LOW-DOSE COLCHICINE AFTER MYOCARDIAL INFARCTION
    Publication number: 20230364040
    Abstract: The invention relates to colchicine for use in a method of treating a patient after having a myocardial infarction (MI), the method including initiating the administration of colchicine at a daily low dose to the patient within about 3 days of the MI.
    Type: Application
    Filed: July 20, 2023
    Publication date: November 16, 2023
    Inventor: Jean-Claude TARDIF
  • GENETIC MARKERS FOR PREDICTING RESPONSIVENESS TO THERAPY WITH HDL-RAISING OR HDL MIMICKING AGENT
    Publication number: 20230151424
    Abstract: Genotyping methods and compositions for selecting patients with cardiovascular disease who will benefit from treatment with HDL-raising or HDL mimicking agent, in particular with a CETP inhibitor/modulator
    Type: Application
    Filed: June 16, 2022
    Publication date: May 18, 2023
    Applicant: Hoffmann-La Roche Inc.
    Inventors: Marie-Pierre Dube, Jean-Claude Tardif
  • CETP inhibitors for therapeutic use
    Patent number: 11549142
    Abstract: The present invention provides genotyping methods and compositions for selecting patients with cardiovascular disease who will benefit from treatment with HDL-raising or HDL mimicking agent, in particular with a CETP inhibitor/modulator.
    Type: Grant
    Filed: June 3, 2020
    Date of Patent: January 10, 2023
    Assignee: Hoffmann-La Roche Inc.
    Inventors: Marie-Pierre Dube, Eric J. Niesor, Jean-Claude Tardif, Ruchi Upmanyu
  • METHODS FOR USING LOW-DOSE COLCHICINE AFTER MYOCARDIAL INFARCTION
    Publication number: 20220401388
    Abstract: The invention features methods of treating a patient after having a myocardial infarction including administering colchicine to a patient determined to have a genetic variant in the genome that is indicative of the patient benefiting from colchicine administration or not to have a genetic variant in the genome that is that is indicative of the patient suffering a gastrointestinal disorder following colchicine administration.
    Type: Application
    Filed: November 13, 2020
    Publication date: December 22, 2022
    Inventors: Marie-Pierre DUBÉ, Jean-Claude TARDIF
  • METHODS OF TREATING ACUTE RESPIRATORY DISTRESS SYNDROME USING COLCHICINE
    Publication number: 20220362181
    Abstract: Disclosed are methods of treating Acute Respiratory Distress Syndrome using colchicine, e.g., by administering colchicine to a subject in need thereof.
    Type: Application
    Filed: April 6, 2022
    Publication date: November 17, 2022
    Inventors: Jean-Claude TARDIF, Jocelyn DUPUIS
  • EARLY ADMINISTRATION OF LOW-DOSE COLCHICINE AFTER MYOCARDIAL INFARCTION
    Publication number: 20220249409
    Abstract: The invention relates to colchicine for use in a method of treating a patient after having a myocardial infarction (MI), the method including initiating the administration of colchicine at a daily low dose to the patient within about 3 days of the MI.
    Type: Application
    Filed: April 27, 2022
    Publication date: August 11, 2022
    Inventor: Jean-Claude TARDIF
  • Genetic markers for predicting responsiveness to therapy with HDL-raising or HDL mimicking agent
    Patent number: 11401554
    Abstract: Genotyping methods and compositions for selecting patients with cardiovascular disease who will benefit from treatment with HDL-raising or HDL mimicking agent, in particular with a CETP inhibitor/modulator.
    Type: Grant
    Filed: January 27, 2020
    Date of Patent: August 2, 2022
    Assignee: Hoffman-La Roche Inc.
    Inventors: Marie-Pierre Dube, Jean-Claude Tardif
  • Early administration of low-dose colchicine after myocardial infarction
    Patent number: 11400063
    Abstract: The invention relates to colchicine for use in a method of treating a patient after having a myocardial infarction (MI), the method including initiating the administration of colchicine at a daily low dose to the patient within about 3 days of the MI.
    Type: Grant
    Filed: November 13, 2020
    Date of Patent: August 2, 2022
    Assignee: INSTITUT DE CARDIOLOGIE DE MONTREAL
    Inventor: Jean-Claude Tardif
  • METHODS FOR TREATING OR PREVENTING CARDIOVASCULAR DISORDERS AND LOWERING RISK OF CARDIOVASCULAR EVENTS
    Publication number: 20210290623
    Abstract: The invention provides compositions and methods useful for treating or preventing cardiovascular disorders and lowering risk of cardiovascular events.
    Type: Application
    Filed: June 1, 2021
    Publication date: September 23, 2021
    Inventors: Marie-Pierre DUBÉ, Jean-Claude TARDIF, Eric RHÉAUME
  • METHODS FOR DELAYING OCCURRENCE OF NEW-ONSET TYPE 2 DIABETES AND FOR SLOWING PROGRESSION OF AND TREATING TYPE 2 DIABETES
    Publication number: 20210236442
    Abstract: The invention provides compositions and methods useful for delaying occurrence of new-onset type 2 diabetes, slowing progression of type 2 diabetes, treating type 2 diabetes, and slowing progression of a complication of type 2 diabetes.
    Type: Application
    Filed: February 5, 2021
    Publication date: August 5, 2021
    Inventors: Marie-Pierre DUBÉ, Jean-Claude TARDIF, Fouzia LAGHRISSI-THODE
  • EARLY ADMINISTRATION OF LOW-DOSE COLCHICINE AFTER MYOCARDIAL INFARCTION
    Publication number: 20210145773
    Abstract: The invention relates to colchicine for use in a method of treating a patient after having a myocardial infarction (MI), the method including initiating the administration of colchicine at a daily low dose to the patient within about 3 days of the MI.
    Type: Application
    Filed: November 13, 2020
    Publication date: May 20, 2021
    Inventor: Jean-Claude TARDIF
  • CETP INHIBITORS FOR THERAPEUTIC USE
    Publication number: 20210017597
    Abstract: The present invention provides genotyping methods and compositions for selecting patients with cardiovascular disease who will benefit from treatment with HDL-raising or HDL mimicking agent, in particular with a CETP inhibitor/modulator.
    Type: Application
    Filed: June 3, 2020
    Publication date: January 21, 2021
    Applicant: Hoffmann-La Roche Inc.
    Inventors: Marie-PIerre Dube, Eric J. Niesor, Jean-Claude Tardif, Ruchi Upmanyu
  • GENETIC MARKERS FOR PREDICTING RESPONSIVENESS TO THERAPY WITH HDL-RAISING OR HDL MIMICKING AGENT
    Publication number: 20200239960
    Abstract: Genotyping methods and compositions for selecting patients with cardiovascular disease who will benefit from treatment with HDL-raising or HDL mimicking agent, in particular with a CETP inhibitor/modulator
    Type: Application
    Filed: January 27, 2020
    Publication date: July 30, 2020
    Applicant: Hoffmann-La Roche Inc.
    Inventors: Marie-Pierre Dube, Jean-Claude Tardif
  • METHODS FOR TREATING OR PREVENTING CARDIOVASCULAR DISORDERS AND LOWERING RISK OF CARDIOVASCULAR EVENTS
    Publication number: 20200222406
    Abstract: The invention provides compositions and methods useful for treating or preventing cardiovascular disorders and lowering risk of cardiovascular events.
    Type: Application
    Filed: January 13, 2020
    Publication date: July 16, 2020
    Inventors: Marie-Pierre DUBÉ, Jean-Claude TARDIF, Eric RHÉAUME
  • CETP inhibitors for therapeutic use
    Patent number: 10711303
    Abstract: The present invention provides genotyping methods and compositions for selecting patients with cardiovascular disease who will benefit from treatment with HDL-raising or HDL mimicking agent, in particular with a CETP inhibitor/modulator.
    Type: Grant
    Filed: August 22, 2018
    Date of Patent: July 14, 2020
    Assignee: Hoffman-La Roche Inc.
    Inventors: Marie-Pierre Dube, Eric J. Niesor, Jean-Claude Tardif, Ruchi Upmanyu
  • Genetic markers for predicting responsiveness to therapy with HDL-raising or HDL mimicking agent
    Patent number: 10584385
    Abstract: Genotyping methods and compositions for selecting patients with cardiovascular disease who will benefit from treatment with HDL-raising or HDL mimicking agent, in particular with a CETP inhibitor/modulator.
    Type: Grant
    Filed: January 25, 2017
    Date of Patent: March 10, 2020
    Assignee: Hoffmann-La Roche Inc.
    Inventors: Marie-Pierre Dube, Jean-Claude Tardif
  • A CO-CULTURE SYSTEM AND METHOD FOR IN VITRO ASSESSMENT OF REVERSE CHOLESTEROL TRANSPORT
    Publication number: 20190284527
    Abstract: The present invention provides a co-culture system and method for assessing cellular cholesterol (Choi) efflux and uptake in vitro. The co-culture system mimics in vivo Choi efflux and uptake in the context of mammalian physiology. The methods and systems provided can be used in some embodiments to evaluate the effect of a pharmacological agent on cellular Choi efflux and uptake or for diagnostic purposes.
    Type: Application
    Filed: May 30, 2017
    Publication date: September 19, 2019
    Inventors: David RHAINDS, Éric RHÉAUME, David BUSSEUIL, Jean-Claude TARDIF
  • CETP INHIBITORS FOR THERAPEUTIC USE
    Publication number: 20190226020
    Abstract: The present invention provides genotyping methods and compositions for selecting patients with cardiovascular disease who will benefit from treatment with HDL-raising or HDL mimicking agent, in particular with a CETP inhibitor/modulator.
    Type: Application
    Filed: August 22, 2018
    Publication date: July 25, 2019
    Applicant: Hoffmann-La Roche Inc.
    Inventors: Marie-Pierre Dube, Eric J. Niesor, Jean-Claude Tardif, Ruchi Upmanyu